Nifty
Sensex
:
:
15932.20
53193.61
-308.10 (-1.90%)
-1014.92 (-1.87%)

Pharmaceuticals & Drugs - Global

Rating :
66/99

BSE: 530199 | NSE: THEMISMED

871.75
18-May-2022
  • Open
  • High
  • Low
  • Previous Close
  •  835.10
  •  879.00
  •  824.55
  •  831.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  3361
  •  28.92
  •  1197.00
  •  475.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 805.02
  • 11.34
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 865.55
  • 0.49%
  • 2.90

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 67.18%
  • 4.82%
  • 22.20%
  • FII
  • DII
  • Others
  • 0%
  • 0.00%
  • 5.80%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.87
  • 1.26
  • 7.88

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 8.86
  • 85.22

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 12.17
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.69
  • 21.11
  • 12.17

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.85
  • 2.53
  • 2.34

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.67
  • 20.09
  • 23.71

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 21
Dec 20
Var%
Sep 21
Sep 20
Var%
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Net Sales
94.92
65.52
44.87%
107.39
54.89
95.65%
112.50
48.49
132.01%
61.77
46.15
33.85%
Expenses
77.63
50.27
54.43%
83.93
45.19
85.73%
72.03
36.19
99.03%
49.52
32.77
51.11%
EBITDA
17.29
15.25
13.38%
23.46
9.70
141.86%
40.47
12.30
229.02%
12.25
13.39
-8.51%
EBIDTM
18.22%
23.28%
21.85%
17.67%
35.97%
25.36%
19.83%
29.00%
Other Income
4.14
0.25
1,556.00%
0.21
2.13
-90.14%
0.35
0.36
-2.78%
0.88
0.38
131.58%
Interest
2.13
2.92
-27.05%
2.05
3.71
-44.74%
2.67
3.00
-11.00%
3.09
3.41
-9.38%
Depreciation
2.36
2.09
12.92%
2.38
2.04
16.67%
2.35
2.04
15.20%
2.38
2.07
14.98%
PBT
16.94
10.49
61.49%
19.25
6.08
216.61%
35.80
7.62
369.82%
7.66
8.29
-7.60%
Tax
4.79
2.02
137.13%
4.13
0.42
883.33%
9.07
1.98
358.08%
1.21
3.09
-60.84%
PAT
12.15
8.47
43.45%
15.12
5.66
167.14%
26.73
5.64
373.94%
6.46
5.19
24.47%
PATM
12.80%
12.92%
14.08%
10.31%
23.76%
11.63%
10.46%
11.25%
EPS
13.54
12.80
5.78%
20.95
8.85
136.72%
33.93
8.44
302.01%
8.76
7.92
10.61%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
376.58
230.67
201.59
183.75
209.50
216.66
232.43
201.88
195.07
173.51
157.72
Net Sales Growth
75.11%
14.43%
9.71%
-12.29%
-3.30%
-6.78%
15.13%
3.49%
12.43%
10.01%
 
Cost Of Goods Sold
142.19
67.35
51.97
58.82
57.75
55.66
71.38
79.51
76.68
74.95
94.19
Gross Profit
234.39
163.33
149.62
124.94
151.75
160.99
161.06
122.37
118.39
98.56
63.52
GP Margin
62.24%
70.81%
74.22%
67.99%
72.43%
74.31%
69.29%
60.62%
60.69%
56.80%
40.27%
Total Expenditure
283.11
181.18
165.93
181.48
184.98
184.29
194.28
183.91
171.01
156.71
170.56
Power & Fuel Cost
-
11.32
11.49
9.70
8.41
9.77
10.83
8.36
10.04
10.03
10.27
% Of Sales
-
4.91%
5.70%
5.28%
4.01%
4.51%
4.66%
4.14%
5.15%
5.78%
6.51%
Employee Cost
-
39.99
44.28
45.69
44.65
40.00
36.30
32.64
31.14
27.27
23.70
% Of Sales
-
17.34%
21.97%
24.87%
21.31%
18.46%
15.62%
16.17%
15.96%
15.72%
15.03%
Manufacturing Exp.
-
21.41
24.01
22.45
27.46
31.30
31.28
21.69
16.38
11.80
12.36
% Of Sales
-
9.28%
11.91%
12.22%
13.11%
14.45%
13.46%
10.74%
8.40%
6.80%
7.84%
General & Admin Exp.
-
12.03
14.05
17.57
18.93
18.86
14.75
13.52
11.72
11.33
9.75
% Of Sales
-
5.22%
6.97%
9.56%
9.04%
8.70%
6.35%
6.70%
6.01%
6.53%
6.18%
Selling & Distn. Exp.
-
14.92
12.28
17.71
18.27
16.70
12.05
10.87
10.06
7.65
5.89
% Of Sales
-
6.47%
6.09%
9.64%
8.72%
7.71%
5.18%
5.38%
5.16%
4.41%
3.73%
Miscellaneous Exp.
-
14.16
7.86
9.54
9.51
11.99
17.69
17.32
14.98
13.68
5.89
% Of Sales
-
6.14%
3.90%
5.19%
4.54%
5.53%
7.61%
8.58%
7.68%
7.88%
9.13%
EBITDA
93.47
49.49
35.66
2.27
24.52
32.37
38.15
17.97
24.06
16.80
-12.84
EBITDA Margin
24.82%
21.45%
17.69%
1.24%
11.70%
14.94%
16.41%
8.90%
12.33%
9.68%
-8.14%
Other Income
5.58
3.62
3.46
2.67
3.49
3.32
3.19
12.59
4.90
3.34
2.94
Interest
9.94
12.71
12.88
11.82
11.87
11.84
12.33
14.53
15.63
15.28
13.55
Depreciation
9.47
8.55
8.27
7.99
7.42
7.47
11.89
11.49
9.36
8.91
7.67
PBT
79.65
31.86
17.97
-14.87
8.74
16.37
17.13
4.54
3.98
-4.05
-31.12
Tax
19.20
5.63
2.09
-1.84
0.10
1.60
1.91
-0.89
1.28
2.27
1.35
Tax Rate
24.11%
17.67%
11.63%
12.37%
1.14%
9.77%
11.15%
-19.60%
32.16%
-56.05%
-4.34%
PAT
60.46
26.23
15.88
-13.01
8.70
14.77
15.22
5.44
2.70
-6.32
-32.47
PAT before Minority Interest
60.46
26.23
15.88
-13.03
8.64
14.77
15.22
5.44
2.70
-6.32
-32.47
Minority Interest
0.00
0.00
0.00
0.02
0.06
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
16.06%
11.37%
7.88%
-7.08%
4.15%
6.82%
6.55%
2.69%
1.38%
-3.64%
-20.59%
PAT Growth
142.23%
65.18%
-
-
-41.10%
-2.96%
179.78%
101.48%
-
-
 
EPS
65.72
28.51
17.26
-14.14
9.46
16.05
16.54
5.91
2.93
-6.87
-35.29

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
218.51
183.02
158.09
168.91
152.44
74.03
59.20
56.53
52.17
58.52
Share Capital
9.19
9.19
9.18
9.18
9.04
8.52
8.47
8.45
8.05
8.05
Total Reserves
208.95
173.35
148.31
159.18
141.36
65.51
50.73
48.08
43.27
50.47
Non-Current Liabilities
24.33
7.51
2.71
6.72
7.60
70.83
82.04
89.97
99.37
71.58
Secured Loans
5.73
0.09
0.14
0.01
0.47
15.89
18.83
24.47
32.08
2.78
Unsecured Loans
16.47
11.76
9.21
11.48
11.93
47.52
55.81
52.30
59.72
62.13
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.54
0.49
0.46
0.39
0.30
Current Liabilities
128.31
154.81
146.69
124.94
124.17
129.66
135.61
137.09
120.36
150.31
Trade Payables
30.79
29.68
35.04
30.55
31.63
34.90
60.15
56.97
51.65
59.03
Other Current Liabilities
39.09
46.86
43.72
29.76
38.13
37.04
16.51
23.68
14.81
12.93
Short Term Borrowings
56.93
76.61
66.86
63.73
53.45
51.88
53.78
52.74
50.55
75.35
Short Term Provisions
1.49
1.66
1.07
0.90
0.95
5.83
5.17
3.71
3.34
3.00
Total Liabilities
371.15
345.34
307.47
300.51
284.21
274.52
276.85
283.59
271.90
280.41
Net Block
133.10
116.31
123.41
125.90
123.71
117.35
122.32
121.26
123.66
133.75
Gross Block
172.24
147.14
146.06
140.78
131.17
212.16
206.19
192.01
185.14
187.89
Accumulated Depreciation
39.14
30.83
22.66
14.87
7.46
94.80
83.87
70.75
61.47
54.14
Non Current Assets
185.67
164.85
157.61
157.47
159.81
141.68
143.38
149.17
148.01
151.01
Capital Work in Progress
2.47
7.54
2.45
2.47
8.95
5.79
3.50
11.63
10.70
6.77
Non Current Investment
44.96
35.47
26.64
24.38
21.83
5.64
4.59
3.59
3.59
0.51
Long Term Loans & Adv.
2.83
2.91
2.67
2.39
3.01
12.19
12.70
12.11
9.79
9.54
Other Non Current Assets
2.31
2.62
2.45
2.33
2.30
0.70
0.28
0.58
0.27
0.45
Current Assets
185.47
180.49
149.86
143.04
124.40
132.83
133.47
134.44
123.89
129.40
Current Investments
0.00
0.00
0.00
0.00
1.05
0.00
0.00
0.00
0.00
0.00
Inventories
58.49
54.61
53.63
49.58
48.44
58.26
62.30
66.34
54.70
47.23
Sundry Debtors
77.61
102.48
72.91
68.63
48.25
47.57
45.56
39.58
32.35
48.13
Cash & Bank
24.63
5.29
3.45
6.91
8.62
14.30
8.70
6.57
12.21
6.70
Other Current Assets
24.73
5.83
5.42
5.34
18.04
12.70
16.92
21.94
24.63
27.35
Short Term Loans & Adv.
18.84
12.28
14.45
12.57
12.72
11.34
15.58
20.57
23.22
26.34
Net Current Assets
57.16
25.68
3.18
18.09
0.23
3.18
-2.14
-2.66
3.53
-20.92
Total Assets
371.14
345.34
307.47
300.51
284.21
274.51
276.85
283.61
271.90
280.41

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
56.98
0.33
10.92
7.86
-1.51
25.76
19.09
8.35
4.45
-14.33
PBT
41.33
26.87
-12.60
11.33
17.56
30.52
19.85
19.61
11.23
-17.57
Adjustment
7.66
9.33
16.74
14.93
15.92
10.05
10.48
8.47
7.72
6.80
Changes in Working Capital
7.90
-35.63
7.08
-19.05
-35.16
-0.57
2.40
-2.82
3.04
11.34
Cash after chg. in Working capital
56.90
0.57
11.22
7.21
-1.67
40.00
32.73
25.26
22.00
0.57
Interest Paid
0.00
0.00
0.00
0.00
0.00
-12.33
-14.53
0.00
0.00
0.00
Tax Paid
0.08
-0.24
-0.30
0.65
0.16
-1.91
0.89
-1.28
-2.27
-1.35
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-15.65
-5.47
-3.72
-0.04
-4.14
-7.17
-6.27
-6.71
-4.56
-11.76
Net Fixed Assets
-20.03
-6.16
-5.34
-3.11
20.82
-6.64
-2.13
-3.68
2.13
-7.75
Net Investments
-0.02
0.06
-0.01
1.01
-1.33
0.01
-0.23
0.00
-3.09
-0.01
Others
4.40
0.63
1.63
2.06
-23.63
-0.54
-3.91
-3.03
-3.60
-4.00
Cash from Financing Activity
-25.65
6.72
-9.94
-9.11
5.27
-13.29
-17.96
1.89
29.33
4.93
Net Cash Inflow / Outflow
15.68
1.59
-2.74
-1.29
-0.38
5.31
-5.14
3.52
29.23
-21.16
Opening Cash & Equivalents
3.34
1.75
4.49
5.78
6.16
-39.67
-34.53
-38.05
-67.28
-46.12
Closing Cash & Equivalent
19.02
3.34
1.75
4.49
5.78
-34.36
-39.67
-34.53
-38.05
-67.28

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
237.41
198.67
171.54
183.39
166.38
86.94
69.91
66.90
63.75
72.69
ROA
7.32%
4.86%
-4.29%
2.95%
5.29%
5.52%
1.94%
0.97%
-2.29%
-11.32%
ROE
13.09%
9.34%
-8.00%
5.42%
13.16%
22.85%
9.40%
5.00%
-11.50%
-43.27%
ROCE
15.21%
11.81%
-1.25%
8.52%
12.92%
14.69%
9.45%
9.53%
5.39%
-8.28%
Fixed Asset Turnover
1.44
1.38
1.28
1.56
1.32
1.13
1.03
1.04
0.94
0.91
Receivable days
142.49
158.78
140.57
100.75
77.33
72.04
76.05
66.90
83.91
130.33
Inventory Days
89.48
97.99
102.51
84.49
86.11
93.26
114.91
112.58
106.28
106.24
Payable days
163.89
75.58
71.78
69.42
73.88
99.57
126.74
123.69
137.24
142.68
Cash Conversion Cycle
68.08
181.20
171.29
115.83
89.56
65.73
64.22
55.79
52.95
93.89
Total Debt/Equity
0.39
0.54
0.52
0.48
0.55
1.73
2.37
2.61
3.02
2.57
Interest Cover
3.51
2.40
-0.26
1.74
2.38
2.39
1.31
1.25
0.74
-1.30

News Update:


  • Themis Medicare gets DCGI’s add on approval for ‘Viralex’
    18th May 2022, 15:35 PM

    Earlier, Viralex was approved by DCGI for restricted emergency use in Covid 19 patients based on the results of two RCT in 499 Indian patients

    Read More
  • Themis Medicare gets DCGI nod for antiviral drug ‘Viralex’
    21st Mar 2022, 12:22 PM

    As per the results of a double-blind RCT, the drug helps in early relief of the clinical symptoms in mild to moderate COV1D- 19 patients

    Read More
  • Themis Medicare gets approval for immunomodulatory antiviral drug ‘VIRALEX’
    4th Mar 2022, 09:20 AM

    VIRALEX would be available on prescription

    Read More
  • Themis Medicare - Quarterly Results
    11th Feb 2022, 14:41 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.